Duopharma closed its fiscal year 2023 (FY2023) with net profit declining 24.91% to RM52.65 million from RM70.11 million, impacted by lower margins and higher finance costs.

Duopharma Biotech Berhad (KLSE:DPHARMA) will increase its dividend on the 19th of March to MYR0.02, which is 11% higher than last year's payment from the same period of MYR0.018. This takes the ...

Leonard Ariff Abdul Shatar, Group Managing Director of Duopharma Biotech Berhad, expressed optimism looking ahead to prospects in 2025. "In 2024, despite ongoing pressures from elevated ...

PETALING JAYA: Duopharma Biotech Bhd ’s future earnings will still be underpinned by robust drug product purchase list or APPL for the government as well as potential synergies generated by ...

KUALA LUMPUR: Duopharma Biotech Bhd today said the government has accepted the tender offer from its wholly owned subsidiary Duopharma Marketing Sdn Bhd (DMktg) to supply Insugen, a human insulin ...

If you want to know who really controls Duopharma Biotech Berhad (KLSE:DPHARMA), then you'll have to look at the makeup of its share registry. And the group that holds the biggest piece of the pie are ...